Aurora Cannabis Inc. (TSX:ACB) Q2 Shows Big Growth in Pot Sales

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) reported a strong rise in revenue in Q2, but also a big loss.

| More on:
Arrowings ascending on a chalkboard

Image source: Getty Images.

Aurora Cannabis (TSX:ACB)(NYSE:ABC) released its second-quarter results for fiscal 2019 on Monday, which saw a big jump in revenue. The pot producer benefited from higher cannabis sales following Canada’s legalization of recreational cannabis in October.

Big revenue, big loss

Aurora reported revenue of $54.2 million for the second quarter ended December 31, 2018. This is more than four times the revenue of $11.7 million it earned in the same quarter a year ago. Analysts were expecting a lower revenue of $51.84 million. Marijuana sales rose to 6,999 kg from 1,162 kg.

Aurora sold about 20% of Canada’s recreational marijuana in the quarter, with sales of $21.6 million. This quarter is the first to include sales of recreational cannabis after it has been legalized in Canada on October 17.

On a less happy note, Aurora incurred a loss of $237.8 million, reflecting a sharp decline in Aurora’s investments in other pot companies. Analysts were expecting a much smaller loss of $62.05 million. However, this appears to be a temporary situation, as the company promises gains in coming quarters.

Earnings are expected to grow to $0.07 per share in 2019 and to $0.12 per share in 2020. Sales are expected to reach $338 million in 2019; in 2020, they are estimated to grow to $839 million.

Growth through international expansion and strategic partnerships

The Edmonton-based company is one of the world’s largest cannabis producers, with a funded capacity of more than 500,000 kilograms a year and operations in 22 countries across five continents. Aurora has 15 wholly owned subsidiary companies, including MedReleaf and CanniMed Therapeutics.

The cannabis producer continues to grow its international footprint. A few hours before releasing its quarterly results, Aurora announced that it has completed its first commercial export of medical cannabis oil to the United Kingdom from a certified pharmacy.

Aurora is one of the first Canadian companies to commercially supply cannabis-based medicines into the U.K. under the new legal framework that came into effect on November 1, 2018.

“Our brands continue to resonate extremely well in the consumer market, our patient numbers continue to increase steadily, and we have maintained our market leadership in Germany and other key international markets,” said Aurora’s CEO Terry Booth in a statement.

To facilitate its growth, the company has invested in and established strategic partnerships with a range of leading innovators, including Radient Technologies and Hempco Food and Fiber.

Aurora’s most recent acquisition, Whistler Medical Marijuana, is expected to provide it with a suite of premium and organic certified products.

Uncertainties and volatility in the stock

While Aurora’s stock is up nearly 50% year-to-date, trading a few cents below $10, the price is still far from the all-time high of $16.24 it reached on October 16, the day before legalization. The stock P/E is becoming more reasonable – the trailing P/E is 38.3 versus a five-year average of 150.3 – and I see this as an opportunity to buy the stock.

While there is strong upside potential for Aurora’s stock, be ready to tolerate a great deal of volatility. Cannabis sales have been legal in Canada only since October, and supply chain difficulties have emerged. But once these issues are resolved, we could see significant top-line growth, as recreational sales are likely below market demand.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf owns shares of Aurora Cannabis.

More on Investing

stock analysis

Buy the Dip: 2 Stocks to Buy Today and Hold for the Next 5 Years

These Canadian stocks are trading at discounted valuations, providing an opportunity for buying the dip.

Read more »

bulb idea thinking

Safety in Size? 2 of the Bluest Blue-Chip Stocks I’d Buy Now

TC Energy (TSX:TRP) and another cash cow have huge dividend yields for safe investors.

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

Question marks in a pile
Dividend Stocks

Where Will Brookfield Infrastructure Partners Stock Be in 5 Years?

Brookfield Infrastructure Partners (TSX:BIP.UN) kicked off 2024 with a bang. Where will it be in five years?

Read more »

TFSA and coins

TFSA Investors: 3 Incredible Stocks for 2024

Are you looking for stocks to buy and hold for years for your TFSA? These three stocks could deliver exceptional…

Read more »

A person looks at data on a screen
Stocks for Beginners

3 Warren Buffett Stocks to Hold Forever

Warren Buffett sold some shares in Apple (NASDAQ:AAPL), and the market had questions.

Read more »

Dividend Stocks

Golden Years Gain: Your CPP Benefits at Age 70

CPP users delaying pension payments until 70 will receive substantial monthly income streams in the golden years.

Read more »

data analytics, chart and graph icons with female hands typing on laptop in background
Dividend Stocks

3 Dividend Stocks You Can Safely Hold for Decades

Top TSX dividend stocks are on sale.

Read more »